Curanex Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$10.5MTTM through 30 Jun 2026
Free Cash Flow -$12.1MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
Returns
-85.3%ROE
-30.0%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio81.93x
Net Debt-$4Mnet cash position
Cash & Equivalents$2.9M
Quality Metrics
Altman Z-Score6.19
Piotroski F-Score1 / 9
Multi-Year Trend
Diluted EPS-$0.39TTMFY2025: $-0.17
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Botanical Drug Development | $0 | View detailsThe company is focused on completing IND-enabling GLP toxicology and pharmacokinetic studies, with plans to initiate Phase I clinical trials in Australia in Q4 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.